BioVersys (BIOV) is a Swiss clinical-stage biopharmaceutical company developing novel anti-infectives to address antimicrobial resistance (AMR). Lead asset BV100 targets carbapenem-resistant Acinetobacter baumannii (CRAB) infections, classified by the WHO as a critical priority pathogen. BIOV’s sec
